P/B
0,2
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
$1.8M
Market Cap • 10/30/2026
2007
(19 years)
Founded
2012
(14 years ago)
IPO
NASDAQ
Listing Exchange
Australia
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
9,6
EPS
—
Market Cap
Market Cap
1,8M
EV
1,5M
EV/Revenue
0
EV/EBITDA
-0,1
EV/EBIT
-0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-349,1%
Total Yield
-349,1%
Payout
0%
Retained Earnings
-144,5M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
494,8%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
58,6%
CAGR Net Income 5Y
56,2%
CAGR OCF 5Y
37,8%
Leverage
N.D./EBITDA
0
Debt/Equity
0%
Current Ratio
2,5
Quick Ratio
0,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!